Key DNA Screening Deadline Arrives With No Replacement Framework in Place

A biosecurity policy milestone landed yesterday with an asterisk attached.

October 13, 2026 was the date the White House Office of Science and Technology Policy's Framework for Nucleic Acid Synthesis Screening was supposed to become meaningfully stricter. According to the framework text reviewed by the Johns Hopkins Center for Health Security's gene-synthesis screening project, providers were required as of yesterday to reduce their screening window from 200 nucleotides to 50, screen for sequences that could be assembled into sequences of concern across bulk or repeat orders, and expand the definition of sequences of concern to include any sequence known to contribute to pathogenicity or toxicity, even if not derived from a formally regulated agent.

Those are not trivial upgrades. The 200-nucleotide threshold that industry has operated under since the 2024 framework's April 2024 release left a documented gap: short oligonucleotides can be ordered in pieces and assembled into longer, dangerous constructs. The tighter 50-nucleotide window was specifically designed to close that fragmentation route.

The problem, as a Substack analysis published October 2 by Thom Aster noted, is that the framework requiring those improvements is itself legally adrift. On May 5, 2025, President Trump signed Executive Order 14292, which expressly named the 2024 OSTP Framework and directed OSTP to revise or replace it within 90 days. That 90-day clock expired in August 2025. As of October 1, 2026, according to Aster's review of the responsible HHS/ASPR page, federal agencies still point to the 2024 rules and say a replacement will be issued when available.

A Frontiers in Bioengineering and Biotechnology article published in September 2026 put the structural problem plainly: the 2024 DURC-PEPP Policy whose planned implementation was superseded by EO 14292 left a revised or replacement federal policy still under development as of the paper's final search date in late July.

Multiple legislative efforts to put binding teeth into synthesis screening have also stalled. According to biosecurityhandbook.com, updated as of this month, the Securing Gene Synthesis Act, the Nucleic Acid Standards for Biosecurity Act, and the Gene Synthesis Safety and Security Act all failed to advance. California has a state law that mirrors several framework provisions, but provisions taking effect October 13 federally don't apply under that state chapter until October 2027.

The practical consequence is a split screen. Industry providers who self-attest to following the OSTP framework are now, in principle, obligated to meet the tighter October 13 standards. NIH and other federal funders require researchers to buy synthetic nucleic acids only from providers that self-attest to framework compliance. But the framework those providers are attesting to is under an outstanding executive order to be replaced, and no replacement exists. The enforcement architecture, such as it ever was, is voluntary at the federal level and geographically spotty at the state level.

This is a structural assessment, confidence moderate: the screening gap at the oligonucleotide level is real and documented. Whether any actor has exploited it is not established in open source. The dual-use ambiguity here is genuine, not rhetorical. The same short-fragment, assemble-on-demand workflow that makes commercial gene synthesis efficient is the same one that evades a 200-nucleotide screening floor.

A separate line of evidence worth watching: a paper published in Science on June 5 by KAIST professor Seokbeom Kwon, based on an analysis of approximately 600,000 research papers, found that tightening oversight in a single country may impose disproportionate costs on that country's science while having structural limits in preventing equivalent research abroad. That's not an argument against oversight. It's an argument that unilateral voluntary frameworks don't solve the problem they're designed to solve.

OSTP has not publicly stated when a revised framework will appear. ETL Newswire has submitted a records request for any interagency group assessment completed before the October 13 deadline, as the 2024 framework directed.

Sources cited:
- Johns Hopkins Center for Health Security, Gene Synthesis Screening FAQ (https://genesynthesisscreening.centerforhealthsecurity.org/faqs-1)
- Thom Aster, 'The Missing DNA Rulebook' (Substack, Oct. 2, 2026) (https://thomaster.substack.com/p/the-missing-dna-rulebook)
- OSTP Framework for Nucleic Acid Synthesis Screening (Biden White House, April 2024) (https://bidenwhitehouse.archives.gov/wp-content/uploads/2024/04/Nucleic-Acid_Synthesis_Screening_Framework.pdf)
- Frontiers in Bioengineering and Biotechnology, 'A national framework for managing dual-use research of concern' (Aug. 30, 2026) (https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1819510/full)
- Biosecurity Handbook, DNA Synthesis Screening (updated Aug. 2026) (https://biosecurityhandbook.com/biotechnology/dna-synthesis-screening.html)
- Homeland Security Newswire, KAIST dual-use research analysis (June 8, 2026) (https://www.homelandsecuritynewswire.com/dr20260608-first-largescale-empirical-analysis-of-dualuse-research-and-security-oversight)
- Frontiers in Bioengineering and Biotechnology, safe harbor information sharing and synthesis screening (Sep. 2026) (https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1870125/xml)